1
|
Petgrave M, Ramgoolam SD, Ganesan A. Deciphering the Molecular Association of Human CRIP1a with an Agonist-Bound Cannabinoid Receptor 1. J Chem Inf Model 2024; 64:499-517. [PMID: 38159053 DOI: 10.1021/acs.jcim.3c01579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
Cannabinoid receptor 1 (CB1) is a class A G-protein-coupled receptor that plays important roles in several physiological and pathophysiological processes. Therefore, targeted regulation of CB1 activity is a potential therapeutic strategy for several diseases, including neurological disorders. Apart from cannabinoid ligands, CB1 signaling can also be regulated by different CB1-associated proteins. In particular, the cannabinoid receptor interacting protein 1a (CRIP1a) associates with an activated CB1 receptor and alters the G-protein selectivity, thereby reducing the agonist-mediated signal transduction of the CB1 receptor. Experimental evidence suggests that two peptides corresponding to the distal and central C-terminal segments of CB1 could interact with CRIP1a. However, our knowledge of the molecular basis of CB1-CRIP1a recognition is still limited. In this work, we use an extensive combination of computational methods to build the first comprehensive atomistic model human CB1-CRIP1a complex. Our model provides novel structural insights into the interactions of CRIP1a with a membrane-embedded, complete, agonist-bound CB1 receptor in humans. Our results highlight the key residues that stabilize the CB1-CRIP1a complex, which will be useful to guide in vitro mutagenesis experiments. Furthermore, our human CB1-CRIP1a complex presents a model system for structure-based drug design to target this physiologically important complex for modulating CB1 activity.
Collapse
Affiliation(s)
- Maya Petgrave
- ArGan'sLab, School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, Ontario N2G 1C5, Canada
| | - Shubham Devesh Ramgoolam
- ArGan'sLab, School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, Ontario N2G 1C5, Canada
| | - Aravindhan Ganesan
- ArGan'sLab, School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, Ontario N2G 1C5, Canada
| |
Collapse
|
2
|
Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ. Mechanisms of cannabinoid tolerance. Biochem Pharmacol 2023; 214:115665. [PMID: 37348821 PMCID: PMC10528043 DOI: 10.1016/j.bcp.2023.115665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 06/09/2023] [Accepted: 06/13/2023] [Indexed: 06/24/2023]
Abstract
Cannabis has been used recreationally and medically for centuries, yet research into understanding the mechanisms of its therapeutic effects has only recently garnered more attention. There is evidence to support the use of cannabinoids for the treatment of chronic pain, muscle spasticity, nausea and vomiting due to chemotherapy, improving weight gain in HIV-related cachexia, emesis, sleep disorders, managing symptoms in Tourette syndrome, and patient-reported muscle spasticity from multiple sclerosis. However, tolerance and the risk for cannabis use disorder are two significant disadvantages for cannabinoid-based therapies in humans. Recent work has revealed prominent sex differences in the acute response and tolerance to cannabinoids in both humans and animal models. This review will discuss evidence demonstrating cannabinoid tolerance in rodents, non-human primates, and humans and our current understanding of the neuroadaptations occurring at the cannabinoid type 1 receptor (CB1R) that are responsible tolerance. CB1R expression is downregulated in tolerant animals and humans while there is strong evidence of CB1R desensitization in cannabinoid tolerant rodent models. Throughout the review, critical knowledge gaps are indicated and discussed, such as the lack of a neuroimaging probe to assess CB1R desensitization in humans. The review discusses the intracellular signaling pathways that are responsible for mediating CB1R desensitization and downregulation including the action of G protein-coupled receptor kinases, β-arrestin2 recruitment, c-Jun N-terminal kinases, protein kinase A, and the intracellular trafficking of CB1R. Finally, the review discusses approaches to reduce cannabinoid tolerance in humans based on our current understanding of the neuroadaptations and mechanisms responsible for this process.
Collapse
Affiliation(s)
- Mary K Piscura
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA; Department of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Auburn, AL 36832, USA
| | | | - Robert C Barnes
- Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
| | - Swarup Mitra
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA
| | - Josée Guindon
- Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
| | - Daniel J Morgan
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA.
| |
Collapse
|
3
|
Abstract
Cannabinoid receptors 1 and 2 (CB1 and CB2) are implicated in a range of physiological processes and have gained attention as promising therapeutic targets for a number of diseases. Protein-protein interactions play an integral role in modulating G protein-coupled receptor (GPCR) expression, subcellular distribution and signaling, and the identification and characterization of these will not only improve our understanding of GPCR function and biology, but may provide a novel avenue for therapeutic intervention. A variety of techniques are currently being used to investigate GPCR protein-protein interactions, including Förster/fluorescence and bioluminescence resonance energy transfer (FRET and BRET), proximity ligation assay (PLA), and bimolecular fluorescence complementation (BiFC). However, the reliable application of these methodologies is dependent on the use of appropriate controls and the consideration of the physiological context. Though not as extensively characterized as some other GPCRs, the investigation of CB1 and CB2 interacting proteins is a growing area of interest, and a range of interacting partners have been identified to date. This review summarizes the current state of the literature regarding the cannabinoid receptor interactome, provides commentary on the methodologies and techniques utilized, and discusses future perspectives.
Collapse
Affiliation(s)
- Caitlin R M Oyagawa
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
| | - Natasha L Grimsey
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
| |
Collapse
|
4
|
Shepard RD, Nugent FS. Targeting Endocannabinoid Signaling in the Lateral Habenula as an Intervention to Prevent Mental Illnesses Following Early Life Stress: A Perspective. Front Synaptic Neurosci 2021; 13:689518. [PMID: 34122037 PMCID: PMC8194269 DOI: 10.3389/fnsyn.2021.689518] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 04/29/2021] [Indexed: 12/21/2022] Open
Abstract
Adverse events and childhood trauma increase the susceptibility towards developing psychiatric disorders (substance use disorder, anxiety, depression, etc.) in adulthood. Although there are treatment strategies that have utility in combating these psychiatric disorders, little attention is placed on how to therapeutically intervene in children exposed to early life stress (ELS) to prevent the development of later psychopathology. The lateral habenula (LHb) has been a topic of extensive investigation in mental health disorders due to its prominent role in emotion and mood regulation through modulation of brain reward and motivational neural circuits. Importantly, rodent models of ELS have been shown to promote LHb dysfunction. Moreover, one of the potential mechanisms contributing to LHb neuronal and synaptic dysfunction involves endocannabinoid (eCB) signaling, which has been observed to critically regulate emotion/mood and motivation. Many pre-clinical studies targeting eCB signaling suggest that this neuromodulatory system could be exploited as an intervention therapy to halt maladaptive processes that promote dysfunction in reward and motivational neural circuits involving the LHb. In this perspective article, we report what is currently known about the role of eCB signaling in LHb function and discuss our opinions on new research directions to determine whether the eCB system is a potentially attractive therapeutic intervention for the prevention and/or treatment of ELS-associated psychiatric illnesses.
Collapse
Affiliation(s)
- Ryan D Shepard
- Department of Pharmacology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| | - Fereshteh S Nugent
- Department of Pharmacology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| |
Collapse
|
5
|
Chen D, Wu H, Feng X, Chen Y, Lv Z, Kota VG, Chen J, Wu W, Lu Y, Liu H, Zhang Y, Zheng S, Wu J. DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination. Hepatology 2021; 73:1816-1835. [PMID: 32955740 DOI: 10.1002/hep.31561] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 08/10/2020] [Accepted: 08/11/2020] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND AIMS Methylation landscape is important for maintaining the silence of cannabinoid receptor-interacting protein 1 (CNRIP1) in some tumors. However, the role of CNRIP1 in intrahepatic cholangiocarcinoma (ICC) remains poorly defined. APPROACH AND RESULTS In our study, we showed that CNRIP1 was down-regulated in ICC tissues, and low expression of CNRIP1 was significantly associated with poor prognosis of patients with ICC in 3-year overall survival and tumor-free survival. Investigating the genomic DNA methylation profile, we disclosed a CpG island site named CNRIP1 MS-2 (CNRIP1 methylation site-2) that contributes to the down-regulation of CNRIP1. In addition, the methylation level of CNRIP1 MS-2 was correlated to the pathological grade, metastasis, and tumor-node-metastasis classification in ICC. Notably, we observed that CNRIP1 suppressed tumor cell migration, invasion, and proliferation by inhibiting the activity of pyruvate kinase M2 (PKM2). Sustained overexpression of CNRIP1 suppressed the in vivo tumor growth in a mouse xenograft model. It was also found that CNRIP1 overexpression activated Parkin (an E3 ubiquitin ligase), which resulted in the protein degradation of PKM2 in ICC cells. CONCLUSIONS We identified that CNRIP1 acted as a putative tumor suppressor in ICC, which suggested that CNRIP1 could be a candidate biomarker for predicting tumor recurrence in patients with ICC. Furthermore, these findings highlight a potential therapeutic approach in targeting the CNRIP1/Parkin/PKM2 pathway for the treatment of ICC.
Collapse
Affiliation(s)
- Diyu Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
- Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang, China
| | - Hao Wu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Xiaode Feng
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Yunhao Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Zhen Lv
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Vishnu Goutham Kota
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Junru Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Wenxuan Wu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Yuejie Lu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Hua Liu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Yanpeng Zhang
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
| | - Shusen Zheng
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
- Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang, China
| | - Jian Wu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Key Laboratory of Combined Multiorgan Transplantation, National Health Commission, Hangzhou, Zhejiang, China
- Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China
- Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang, China
| |
Collapse
|
6
|
Liu Z, Iyer MR, Godlewski G, Jourdan T, Liu J, Coffey NJ, Zawatsky CN, Puhl HL, Wess J, Meister J, Liow JS, Innis RB, Hassan SA, Lee YS, Kunos G, Cinar R. Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB 1R) Antagonist. ACS Pharmacol Transl Sci 2021; 4:1175-1187. [PMID: 34151207 PMCID: PMC8204328 DOI: 10.1021/acsptsci.1c00048] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Indexed: 12/31/2022]
Abstract
Seven-transmembrane receptors signal via G-protein- and β-arrestin-dependent pathways. We describe a peripheral CB1R antagonist (MRI-1891) highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation. In obese wild-type and βArr2-knockout (KO) mice, MRI-1891 treatment reduces food intake and body weight without eliciting anxiety even at a high dose causing partial brain CB1R occupancy. By contrast, the unbiased global CB1R antagonist rimonabant elicits anxiety in both strains, indicating no βArr2 involvement. Interestingly, obesity-induced muscle insulin resistance is improved by MRI-1891 in wild-type but not in βArr2-KO mice. In C2C12 myoblasts, CB1R activation suppresses insulin-induced akt-2 phosphorylation, preventable by MRI-1891, βArr2 knockdown or overexpression of CB1R-interacting protein. MRI-1891, but not rimonabant, interacts with nonpolar residues on the N-terminal loop, including F108, and on transmembrane helix-1, including S123, a combination that facilitates βArr2 bias. Thus, CB1R promotes muscle insulin resistance via βArr2 signaling, selectively mitigated by a biased CB1R antagonist at reduced risk of central nervous system (CNS) side effects.
Collapse
Affiliation(s)
- Ziyi Liu
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Malliga R Iyer
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Grzegorz Godlewski
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Tony Jourdan
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Jie Liu
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Nathan J Coffey
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Charles N Zawatsky
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Henry L Puhl
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Jürgen Wess
- Laboratory of Bioorganic Chemistry, National Institute on Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland 20892-0001, United States
| | - Jaroslawna Meister
- Laboratory of Bioorganic Chemistry, National Institute on Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland 20892-0001, United States
| | - Jeih-San Liow
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892-9663, United States
| | - Robert B Innis
- Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892-9663, United States
| | - Sergio A Hassan
- Bioinformatics and Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Yong Sok Lee
- Bioinformatics and Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - George Kunos
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| | - Resat Cinar
- Laboratory of Physiologic Studies and Section on Cellular Biophotonics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9304, United States
| |
Collapse
|
7
|
Oliver EE, Hughes EK, Puckett MK, Chen R, Lowther WT, Howlett AC. Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease. Biomolecules 2020; 10:biom10121609. [PMID: 33261012 PMCID: PMC7761089 DOI: 10.3390/biom10121609] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Revised: 11/23/2020] [Accepted: 11/24/2020] [Indexed: 12/15/2022] Open
Abstract
Endocannabinoid signaling depends upon the CB1 and CB2 cannabinoid receptors, their endogenous ligands anandamide and 2-arachidonoylglycerol, and intracellular proteins that mediate responses via the C-terminal and other intracellular receptor domains. The CB1 receptor regulates and is regulated by associated G proteins predominantly of the Gi/o subtypes, β-arrestins 1 and 2, and the cannabinoid receptor-interacting protein 1a (CRIP1a). Evidence for a physiological role for CRIP1a is emerging as data regarding the cellular localization and function of CRIP1a are generated. Here we summarize the neuronal distribution and role of CRIP1a in endocannabinoid signaling, as well as discuss investigations linking CRIP1a to development, vision and hearing sensory systems, hippocampus and seizure regulation, and psychiatric disorders including schizophrenia. We also examine the genetic and epigenetic association of CRIP1a within a variety of cancer subtypes. This review provides evidence upon which to base future investigations on the function of CRIP1a in health and disease.
Collapse
Affiliation(s)
- Emily E. Oliver
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 20157, USA; (E.E.O.); (E.K.H.); (M.K.P.); (R.C.)
- Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Winston-Salem, NC 20157, USA;
| | - Erin K. Hughes
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 20157, USA; (E.E.O.); (E.K.H.); (M.K.P.); (R.C.)
- Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Winston-Salem, NC 20157, USA;
| | - Meaghan K. Puckett
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 20157, USA; (E.E.O.); (E.K.H.); (M.K.P.); (R.C.)
| | - Rong Chen
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 20157, USA; (E.E.O.); (E.K.H.); (M.K.P.); (R.C.)
| | - W. Todd Lowther
- Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Winston-Salem, NC 20157, USA;
| | - Allyn C. Howlett
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 20157, USA; (E.E.O.); (E.K.H.); (M.K.P.); (R.C.)
- Correspondence: ; Tel.: +1-336-716-8545
| |
Collapse
|
8
|
Lyons EL, Leone-Kabler S, Kovach AL, Thomas BF, Howlett AC. Cannabinoid receptor subtype influence on neuritogenesis in human SH-SY5Y cells. Mol Cell Neurosci 2020; 109:103566. [PMID: 33049367 DOI: 10.1016/j.mcn.2020.103566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 10/01/2020] [Accepted: 10/06/2020] [Indexed: 10/23/2022] Open
Abstract
Human SH-SY5Y neuroblastoma cells stably expressing exogenous CB1 (CB1XS) or CB2 (CB2XS) receptors were developed to investigate endocannabinoid signaling in the extension of neuronal projections. Expression of cannabinoid receptors did not alter proliferation rate, viability, or apoptosis relative to parental SH-SY5Y. Transcripts for endogenous cannabinoid system enzymes (diacylglycerol lipase, monoacylglycerol lipase, α/β-hydrolase domain containing proteins 6 and 12, N-acyl phosphatidylethanolamine-phospholipase D, and fatty acid amide hydrolase) were not altered by CB1 or CB2 expression. Endocannabinoid ligands 2-arachidonoylglycerol (2-AG) and anandamide were quantitated in SH-SY5Y cells, and diacylglycerol lipase inhibitor tetrahydrolipstatin decreased 2-AG abundance by 90% but did not alter anandamide abundance. M3 muscarinic agonist oxotremorine M, and inhibitors of monoacylglycerol lipase and α/β hydrolase domain containing proteins 6 &12 increased 2-AG abundance. CB1 receptor expression increased lengths of short (<30 μm) and long (>30 μm) projections, and this effect was significantly reduced by tetrahydrolipstatin, indicative of stimulation by endogenously produced 2-AG. Pertussis toxin, Gβγ inhibitor gallein, and β-arrestin inhibitor barbadin did not significantly alter long projection length in CB1XS, but significantly reduced short projections, with gallein having the greatest inhibition. The rho kinase inhibitor Y27632 increased CB1 receptor-mediated long projection extension, indicative of actin cytoskeleton involvement. CB1 receptor expression increased GAP43 and ST8SIA2 mRNA and decreased ITGA1 mRNA, whereas CB2 receptor expression increased NCAM and SYT mRNA. We propose that basal endogenous production of 2-AG provides autocrine stimulation of CB1 receptor signaling through Gi/o, Gβγ, and β-arrestin mechanisms to promote neuritogenesis, and rho kinase influences process extension.
Collapse
Affiliation(s)
- Erica L Lyons
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, One Medical Center Blvd., Winston-Salem, NC 27157, USA.
| | - Sandra Leone-Kabler
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, One Medical Center Blvd., Winston-Salem, NC 27157, USA.
| | - Alexander L Kovach
- Discovery Sciences, RTI International, PO Box 12194, Research Triangle Park, NC 27709, USA.
| | - Brian F Thomas
- Discovery Sciences, RTI International, PO Box 12194, Research Triangle Park, NC 27709, USA.
| | - Allyn C Howlett
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, One Medical Center Blvd., Winston-Salem, NC 27157, USA.
| |
Collapse
|
9
|
Kwon HJ, Kim DS, Kim W, Jung HY, Yu YH, Ju YI, Park DK, Hwang IK, Kim DW, Yoo DY. Tat-Cannabinoid Receptor Interacting Protein Reduces Ischemia-Induced Neuronal Damage and Its Possible Relationship with 14-3-3η. Cells 2020; 9:cells9081827. [PMID: 32756411 PMCID: PMC7465282 DOI: 10.3390/cells9081827] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 07/20/2020] [Accepted: 07/31/2020] [Indexed: 12/14/2022] Open
Abstract
Cannabinoid receptor-interacting protein 1a (CRIP1a) binds to the C-terminal domain of cannabinoid 1 receptor (CB1R) and regulates CB1R activities. In this study, we made Tat-CRIP1a fusion proteins to enhance CRIP1a penetration into neurons and brain and to evaluate the function of CRIP1a in neuroprotection following oxidative stress in HT22 hippocampal cells and transient forebrain ischemia in gerbils. Purified exogenous Tat-CRIP1a was penetrated into HT22 cells in a time and concentration-dependent manner and prevented H2O2-induced reactive oxygen species formation, DNA fragmentation, and cell damage. Tat-CRIP1a fusion protein also ameliorated the reduction of 14-3-3η expression by H2O2 treatment in HT22 cells. Ischemia–reperfusion damage caused motor hyperactivity in the open field test of gerbils; however, the treatment of Tat-CRIP1a significantly reduced hyperactivity 1 day after ischemia. Four days after ischemia, the administration of Tat-CRIP1a restored the loss of pyramidal neurons and decreased reactive astrocytosis and microgliosis induced by ischemic damage in the hippocampal cornu Ammonis (CA)1 region. Ischemic damage decreased 14-3-3η expression in all hippocampal sub-regions 4 days after ischemia; however, the treatment of Tat-CRIP1 ameliorated the reduction of 14-3-3η expression. These results suggest that Tat-CRIP1a attenuates neuronal damage and hyperactivity induced by ischemic damage, and it restores normal expression levels of 14-3-3η protein in the hippocampus.
Collapse
Affiliation(s)
- Hyun Jung Kwon
- Department of Biochemistry and Molecular Biology, Research Institute of Oral Sciences, College of Dentistry, Gangneung-Wonju National University, Gangneung 25457, Korea;
| | - Duk-Soo Kim
- Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 31151, Korea; (D.-S.K.); (Y.H.Y.); (Y.I.J.); (D.-K.P.)
| | - Woosuk Kim
- Department of Biomedical Sciences and Research Institute for Bioscience and Biotechnology, Hallym University, Chuncheon 24252, Korea;
| | - Hyo Young Jung
- Department of Anatomy and Cell Biology, College of Veterinary Medicine, and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Korea; (H.Y.J.); (I.K.H.)
| | - Yeon Hee Yu
- Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 31151, Korea; (D.-S.K.); (Y.H.Y.); (Y.I.J.); (D.-K.P.)
| | - Young In Ju
- Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 31151, Korea; (D.-S.K.); (Y.H.Y.); (Y.I.J.); (D.-K.P.)
| | - Dae-Kyoon Park
- Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 31151, Korea; (D.-S.K.); (Y.H.Y.); (Y.I.J.); (D.-K.P.)
| | - In Koo Hwang
- Department of Anatomy and Cell Biology, College of Veterinary Medicine, and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Korea; (H.Y.J.); (I.K.H.)
| | - Dae Won Kim
- Department of Biochemistry and Molecular Biology, Research Institute of Oral Sciences, College of Dentistry, Gangneung-Wonju National University, Gangneung 25457, Korea;
- Correspondence: (D.W.K.); (D.Y.Y.); Tel.: +82-33-640-2229 (D.W.K.); +82-41-570-2472 (D.Y.Y.)
| | - Dae Young Yoo
- Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 31151, Korea; (D.-S.K.); (Y.H.Y.); (Y.I.J.); (D.-K.P.)
- Correspondence: (D.W.K.); (D.Y.Y.); Tel.: +82-33-640-2229 (D.W.K.); +82-41-570-2472 (D.Y.Y.)
| |
Collapse
|
10
|
Fletcher-Jones A, Hildick KL, Evans AJ, Nakamura Y, Henley JM, Wilkinson KA. Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R). Front Mol Neurosci 2020; 13:108. [PMID: 32595453 PMCID: PMC7304349 DOI: 10.3389/fnmol.2020.00108] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 05/20/2020] [Indexed: 12/29/2022] Open
Abstract
The endocannabinoid system (ECS) acts as a negative feedback mechanism to suppress synaptic transmission and plays a major role in a diverse range of brain functions including, for example, the regulation of mood, energy balance, and learning and memory. The function and dysfunction of the ECS are strongly implicated in multiple psychiatric, neurological, and neurodegenerative diseases. Cannabinoid type 1 receptor (CB1R) is the most abundant G protein-coupled receptor (GPCR) expressed in the brain and, as for any synaptic receptor, CB1R needs to be in the right place at the right time to respond appropriately to changing synaptic circumstances. While CB1R is found intracellularly throughout neurons, its surface expression is highly polarized to the axonal membrane, consistent with its functional expression at presynaptic sites. Surprisingly, despite the importance of CB1R, the interacting proteins and molecular mechanisms that regulate the highly polarized distribution and function of CB1R remain relatively poorly understood. Here we set out what is currently known about the trafficking pathways and protein interactions that underpin the surface expression and axonal polarity of CB1R, and highlight key questions that still need to be addressed.
Collapse
Affiliation(s)
- Alexandra Fletcher-Jones
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| | - Keri L Hildick
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| | - Ashley J Evans
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| | - Yasuko Nakamura
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| | - Jeremy M Henley
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| | - Kevin A Wilkinson
- Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom
| |
Collapse
|
11
|
Singh P, Ganjiwale A, Howlett AC, Cowsik SM. Molecular Interaction between Distal C-Terminal Domain of the CB 1 Cannabinoid Receptor and Cannabinoid Receptor Interacting Proteins (CRIP1a/CRIP1b). J Chem Inf Model 2019; 59:5294-5303. [PMID: 31769975 DOI: 10.1021/acs.jcim.9b00948] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We have investigated the structure of the distal C-terminal domain of the of the CB1 cannabinoid receptor (CB1R) to study its interactions with CRIP1a and CRIP1b using computational techniques. The amino acid sequence from the distal C-terminal domain of CB1R (G417-L472) was found to be unique, as it does not share sequence similarity with other protein structures, so the structure was predicted using ab initio modeling. The computed model of the distal C-terminal region of CB1R has a helical region between positions 441 and 455. The CRIP1a and CRIP1b were modeled using Rho-GDI 2 as a template. The three-dimensional model of the distal C-terminal domain of the CB1R was docked with both CRIP1a as well as CRIP1b to study the crucial interactions between CB1R and CRIP1a/b. The last nine residues of CB1R (S464TDTSAEAL4722) are known to be a CRIP1a/b binding site. The majority of the key interactions were identified in this region, but notable interactions were also observed beyond theses nine residues. The multiple interactions between Thr418 (CB1R) and Asn61 (CRIP1a) as well as Asp430 (CB1R) and Lys76 (CRIP1a) indicate their importance in the CB1R-CRIP1a interaction. In the case of CRIP1b, multiple hydrogen bond interactions between Asn437 (CB1R) and Glu77 (CRIP1b) were observed. These interactions can be critical for CB1R's interaction with CRIP1a/b, and targeting them for further experimental studies can advance information about CRIP1a/b functionality.
Collapse
Affiliation(s)
- Pratishtha Singh
- School of Life Sciences , Jawaharlal Nehru University , New Delhi - 110067 , India
| | - Anjali Ganjiwale
- Department of Life Sciences , Bangalore University , Bangalore - 560056 , India
| | - Allyn C Howlett
- Department of Physiology and Pharmacology , Wake Forest School of Medicine , Winston-Salem , North Carolina 27157 , United States
| | - Sudha M Cowsik
- School of Life Sciences , Jawaharlal Nehru University , New Delhi - 110067 , India
| |
Collapse
|
12
|
Booth WT, Walker NB, Lowther WT, Howlett AC. Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure. Molecules 2019; 24:molecules24203672. [PMID: 31614728 PMCID: PMC6832298 DOI: 10.3390/molecules24203672] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 10/01/2019] [Accepted: 10/08/2019] [Indexed: 12/22/2022] Open
Abstract
Cannabinoid receptor interacting protein 1a (CRIP1a) is an important CB1 cannabinoid receptor-associated protein, first identified from a yeast two-hybrid screen to modulate CB1-mediated N-type Ca2+ currents. In this paper we review studies of CRIP1a function and structure based upon in vitro experiments and computational chemistry, which elucidate the specific mechanisms for the interaction of CRIP1a with CB1 receptors. N18TG2 neuronal cells overexpressing or silencing CRIP1a highlighted the ability of CRIP1 to regulate cyclic adenosine 3′,5′monophosphate (cAMP) production and extracellular signal-regulated kinase (ERK1/2) phosphorylation. These studies indicated that CRIP1a attenuates the G protein signaling cascade through modulating which Gi/o subtypes interact with the CB1 receptor. CRIP1a also attenuates CB1 receptor internalization via β-arrestin, suggesting that CRIP1a competes for β-arrestin binding to the CB1 receptor. Predictions of CRIP1a secondary structure suggest that residues 34-110 are minimally necessary for association with key amino acids within the distal C-terminus of the CB1 receptor, as well as the mGlu8a metabotropic glutamate receptor. These interactions are disrupted through phosphorylation of serines and threonines in these regions. Through investigations of the function and structure of CRIP1a, new pharmacotherapies based upon the CRIP-CB1 receptor interaction can be designed to treat diseases such as epilepsy, motor dysfunctions and schizophrenia.
Collapse
Affiliation(s)
- William T Booth
- Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
| | - Noah B Walker
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
| | - W Todd Lowther
- Department of Biochemistry and Center for Structural Biology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
- Center for Molecular Signaling, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109, USA.
| | - Allyn C Howlett
- Center for Molecular Signaling, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109, USA.
- Department of Physiology and Pharmacology, Center for Research on Substance Use and Addiction, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
| |
Collapse
|
13
|
Abstract
The endocannabinoid system has emerged as a promising target for the treatment of numerous diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. Thus far, two cannabinoid receptors, CB1 and CB2, have been discovered, which are found predominantly in the central nervous system (CB1) or the immune system (CB2), among other organs and tissues. CB1 receptor ligands have been shown to induce a complex pattern of intracellular effects. The binding of a ligand induces distinct conformational changes in the receptor, which will eventually translate into distinct intracellular signaling pathways through coupling to specific intracellular effector proteins. These proteins can mediate receptor desensitization, trafficking, or signaling. Ligand specificity and selectivity, complex cellular components, and the concomitant expression of other proteins (which either regulate the CB1 receptor or are regulated by the CB1 receptor) will affect the therapeutic outcome of its targeting. With an increased interest in G protein-coupled receptors (GPCR) research, in-depth studies using mutations, biological assays, and spectroscopic techniques (such as NMR, EPR, MS, FRET, and X-ray crystallography), as well as computational modelling, have begun to reveal a set of concerted structural features in Class A GPCRs which relate to signaling pathways and the mechanisms of ligand-induced activation, deactivation, or activity modulation. This review will focus on the structural features of the CB1 receptor, mutations known to bias its signaling, and reported studies of CB1 receptor ligands to control its specific signaling.
Collapse
Affiliation(s)
- Rufaida Al-Zoubi
- Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science & Technology, P.O.BOX 3030, Irbid 22110, Jordan.
| | - Paula Morales
- Departamento de Química-Física Biológica, Instituto de Química Física Rocasolano (IQFR-CSIC), Serrano 119, 28006 Madrid, Spain.
| | - Patricia H Reggio
- Chemistry and Biochemistry Department, UNC Greensboro, Greensboro, NC 27412, USA.
| |
Collapse
|
14
|
Liu Y, Chen LY, Zeng H, Ward R, Wu N, Ma L, Mu X, Li QL, Yang Y, An S, Guo XX, Hao Q, Xu TR. Assessing the real-time activation of the cannabinoid CB1 receptor and the associated structural changes using a FRET biosensor. Int J Biochem Cell Biol 2018; 99:114-124. [PMID: 29626639 DOI: 10.1016/j.biocel.2018.04.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 03/25/2018] [Accepted: 04/04/2018] [Indexed: 11/18/2022]
Abstract
The cannabinoid receptor 1 (CB1) is mainly expressed in the nervous system and regulates learning, memory processes, pain and energy metabolism. However, there is no way to directly measure its activation. In this study, we constructed a CB1 intramolecular fluorescence resonance energy transfer (FRET) sensor, which could measure CB1 activation by monitoring structural changes between the third intracellular loop and the C-terminal tail. CB1 agonists induced a time- and concentration-dependent increase in the FRET signal, corresponding to a reduction in the distance between the third intracellular loop and the C-terminal tail. This, in turn, mobilized intracellular Ca2+, inhibited cAMP accumulation, and increased phosphorylation of the ERK1/2 MAP kinases. The activation kinetics detected using this method were consistent with those from previous reports. Moreover, the increased FRET signal was markedly inhibited by the CB1 antagonist rimonabant, which also reduced phosphorylation of the ERK1/2 MAP kinases. We mutated a single cysteine residue in the sensor (at position 257 or 264) to alanine. Both mutation reduced the agonist-induced increase in FRET signal and structural changes in the CB1 receptor, which attenuated phosphorylation of the ERK1/2 MAP kinases. In summary, our sensor directly assesses the kinetics of CB1 activation in real-time and can be used to monitor CB1 structure and function.
Collapse
Affiliation(s)
- Ying Liu
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Lu-Yao Chen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Hong Zeng
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Richard Ward
- Center for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom
| | - Nan Wu
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Li Ma
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Xi Mu
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Qiu-Lan Li
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Yang Yang
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Su An
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Xiao-Xi Guo
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Qian Hao
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China
| | - Tian-Rui Xu
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, 650500, China.
| |
Collapse
|
15
|
Singh P, Ganjiwale A, Howlett AC, Cowsik SM. In silico interaction analysis of cannabinoid receptor interacting protein 1b (CRIP1b) - CB1 cannabinoid receptor. J Mol Graph Model 2017; 77:311-321. [PMID: 28918320 PMCID: PMC5816684 DOI: 10.1016/j.jmgm.2017.09.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 09/01/2017] [Accepted: 09/02/2017] [Indexed: 01/16/2023]
Abstract
Cannabinoid Receptor Interacting Protein isoform 1b (CRIP1b) is known to interact with the CB1 receptor. Alternative splicing of the CNRIP1 gene produces CRIP1a and CRIP1b with a difference in the third exon only. Exons 1 and 2 encode for a functional domain in both proteins. CRIP1a is involved in regulating CB1 receptor internalization, but the function of CRIP1b is not very well characterized. Since there are significant identities in functional domains of these proteins, CRIP1b is a potential target for drug discovery. We report here predicted structure of CRIP1b followed by its interaction analysis with CB1 receptor by in-silico methods A number of complementary computational techniques, including, homology modeling, ab-initio and protein threading, were applied to generate three-dimensional molecular models for CRIP1b. The computed model of CRIP1b was refined, followed by docking with C terminus of CB1 receptor to generate a model for the CRIP1b- CB1 receptor interaction. The structure of CRIP1b obtained by homology modelling using RHO_GDI-2 as template is a sandwich fold structure having beta sheets connected by loops, similar to predicted CRIP1a structure. The best scoring refined model of CRIP1b in complex with the CB1 receptor C terminus peptide showed favourable polar interactions. The overall binding pocket of CRIP1b was found to be overlapping to that of CRIP1a. The Arg82 and Cys126 of CRIP1b are involved in the majority of hydrogen bond interactions with the CB1 receptor and are possible key residues required for interactions between the CB1 receptor and CRIP1b.
Collapse
Affiliation(s)
- Pratishtha Singh
- School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
| | - Anjali Ganjiwale
- Department of Life Sciences, Bangalore University, Bangalore 560056, India
| | - Allyn C Howlett
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
| | - Sudha M Cowsik
- School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
| |
Collapse
|
16
|
Fin L, Bergamin G, Steiner RA, Hughes SM. The Cannabinoid Receptor Interacting Proteins 1 of zebrafish are not required for morphological development, viability or fertility. Sci Rep 2017; 7:4858. [PMID: 28687732 DOI: 10.1038/s41598-017-05017-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 05/23/2017] [Indexed: 01/10/2023] Open
Abstract
The Cannabinoid Receptor Interacting Protein 1 (Cnrip1) was discovered as an interactor with the intracellular region of Cannabinoid Receptor 1 (CB1R, also known as Cnr1 or CB1). Functional assays in mouse show cannabinoid sensitivity changes and Cnrip1 has recently been suggested to control eye development in Xenopus laevis. Two Cnrip1 genes are described in zebrafish, cnrip1a and cnrip1b. In situ mRNA hybridisation revealed accumulation of mRNA encoding each gene primarily in brain and spinal cord, but also elsewhere. For example, cnrip1b is expressed in forming skeletal muscle. CRISPR/Cas9 genome editing generated predicted null mutations in cnrip1a and cnrip1b. Each mutation triggered nonsense-mediated decay of the respective mRNA transcript. No morphological or behavioural phenotype was observed in either mutant. Moreover, fish lacking both Cnrip1a and Cnrip1b both maternally and zygotically are viable and fertile and no phenotype has so far been detected despite strong evolutionary conservation over at least 400 Myr.
Collapse
|
17
|
Mascia F, Klotz L, Lerch J, Ahmed MH, Zhang Y, Enz R. CRIP1a inhibits endocytosis of G-protein coupled receptors activated by endocannabinoids and glutamate by a common molecular mechanism. J Neurochem 2017; 141:577-591. [PMID: 28295323 DOI: 10.1111/jnc.14021] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 02/17/2017] [Accepted: 03/10/2017] [Indexed: 01/20/2023]
Abstract
The excitability of the central nervous system depends largely on the surface density of neurotransmitter receptors. The endocannabinoid receptor 1 (CB1 R) and the metabotropic glutamate receptor mGlu8 R are expressed pre-synaptically where they reduce glutamate release into the synaptic cleft. Recently, the CB1 R interacting protein cannabinoid receptor interacting protein 1a (CRIP1a) was identified and characterized to regulate CB1 R activity in neurons. However, underlying molecular mechanisms are largely unknown. Here, we identified a common mechanism used by CRIP1a to regulate the cell surface density of two different types of G-protein coupled receptors, CB1 R and mGlu8a R. Five amino acids within the CB1 R C-terminus were required and sufficient to reduce constitutive CB1 R endocytosis by about 72% in the presence of CRIP1a. Interestingly, a similar sequence is present in mGlu8a R and consistently, endocytosis of mGlu8a R depended on CRIP1a, as well. Docking analysis and molecular dynamics simulations identified a conserved serine in CB1 R (S468) and mGlu8a R (S894) that forms a hydrogen bond with the peptide backbone of CRIP1a at position R82. In contrast to mGlu8a R, the closely related mGlu8b R splice-variant carries a lysine (K894) at this position, and indeed, mGlu8b R endocytosis was not affected by CRIP1a. Chimeric constructs between CB1 R, mGlu8a R, and mGlu8b R underline the role of the identified five CRIP1a sensitive amino acids. In summary, we suggest that CRIP1a negatively regulates endocytosis of two different G-protein coupled receptor types, CB1 R and mGlu8a R.
Collapse
Affiliation(s)
- Fabrizio Mascia
- Institut für Biochemie (Emil-Fischer-Zentrum), Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Lisa Klotz
- Institut für Biochemie (Emil-Fischer-Zentrum), Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Judith Lerch
- Institut für Biochemie (Emil-Fischer-Zentrum), Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Mostafa H Ahmed
- Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Yan Zhang
- Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Ralf Enz
- Institut für Biochemie (Emil-Fischer-Zentrum), Universität Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
18
|
Blume LC, Patten T, Eldeeb K, Leone-Kabler S, Ilyasov AA, Keegan BM, O'Neal JE, Bass CE, Hantgan RR, Lowther WT, Selley DE, Howlett ALC. Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites. Mol Pharmacol 2016; 91:75-86. [PMID: 27895162 DOI: 10.1124/mol.116.104638] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 11/23/2016] [Indexed: 01/11/2023] Open
Abstract
Cannabinoid receptor interacting protein 1a (CRIP1a) is a CB1 receptor (CB1R) distal C-terminal-associated protein that alters CB1R interactions with G-proteins. We tested the hypothesis that CRIP1a is capable of also altering CB1R interactions with β-arrestin proteins that interact with the CB1R at the C-terminus. Coimmunoprecipitation studies indicated that CB1R associates in complexes with either CRIP1a or β-arrestin, but CRIP1a and β-arrestin fail to coimmunoprecipitate with each other. This suggests a competition for CRIP1a and β-arrestin binding to the CB1R, which we hypothesized could attenuate the action of β-arrestin to mediate CB1R internalization. We determined that agonist-mediated reduction of the density of cell surface endogenously expressed CB1Rs was clathrin and dynamin dependent and could be modeled as agonist-induced aggregation of transiently expressed GFP-CB1R. CRIP1a overexpression attenuated CP55940-mediated GFP-CB1R as well as endogenous β-arrestin redistribution to punctae, and conversely, CRIP1a knockdown augmented β-arrestin redistribution to punctae. Peptides mimicking the CB1R C-terminus could bind to both CRIP1a in cell extracts as well as purified recombinant CRIP1a. Affinity pull-down studies revealed that phosphorylation at threonine-468 of a CB1R distal C-terminus 14-mer peptide reduced CB1R-CRIP1a association. Coimmunoprecipitation of CB1R protein complexes demonstrated that central or distal C-terminal peptides competed for the CB1R association with CRIP1a, but that a phosphorylated central C-terminal peptide competed for association with β-arrestin 1, and phosphorylated central or distal C-terminal peptides competed for association with β-arrestin 2. Thus, CRIP1a can compete with β-arrestins for interaction with C-terminal CB1R domains that could affect agonist-driven, β-arrestin-mediated internalization of the CB1R.
Collapse
Affiliation(s)
- Lawrence C Blume
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Theresa Patten
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Khalil Eldeeb
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Sandra Leone-Kabler
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Alexander A Ilyasov
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Bradley M Keegan
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Jeremy E O'Neal
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Caroline E Bass
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Roy R Hantgan
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - W Todd Lowther
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - Dana E Selley
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| | - A Llyn C Howlett
- Department of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.)
| |
Collapse
|